Permanent rulemaking would replace IPAY 2026–2028 guidance, enabling predictable annual negotiations of up to 20 drugs and defined manufacturer agreement and renegotiation requirements. Formularies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results